1000 WINTER ST, SUITE 1200, WALTHAM, MA
Announce License Agreement Granting Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
Enter into Obexelimab Funding Agreement for up to $300 Million
Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Material disclosure
Corporate Presentation June 2025 Enabling Patients with Autoimmune Diseases to Reimagine Life
Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Annual Report to Security Holders
Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
Q2
Q1
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Certificate
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership